265 282

Cited 0 times in

Efficacy of clotinab in acute myocardial infarction trial-ST elevation myocardial infarction (ECLAT-STEMI).

Authors
 Jung-Sun Kim  ;  Sang-Min Park  ;  Byeong-Keuk Kim  ;  Young-Guk Ko  ;  Donghoon Choi  ;  Myeong-Ki Hong  ;  In Whan Seong  ;  Byung Ok Kim  ;  Hyeon-Cheol Gwon  ;  Bum Kee Hong  ;  Seung-Jae Tahk  ;  Seong-Wook Park  ;  Chong Jin Kim  ;  Myung-Ho Jeong  ;  Junghan Yoon  ;  Yangsoo Jang 
Citation
 CIRCULATION JOURNAL, Vol.76(2) : 405-413, 2012 
Journal Title
 CIRCULATION JOURNAL 
ISSN
 1346-9843 
Issue Date
2012
MeSH
Aged ; Angioplasty, Balloon, Coronary*/statistics & numerical data ; Antibodies, Monoclonal/administration & dosage* ; Combined Modality Therapy ; Coronary Angiography ; Electrocardiography ; Emergency Medical Services/methods ; Emergency Medical Services/statistics & numerical data ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Fab Fragments/administration & dosage* ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myocardial Infarction/diagnosis ; Myocardial Infarction/drug therapy* ; Myocardial Infarction/mortality ; Platelet Aggregation Inhibitors/administration & dosage* ; Prospective Studies ; Risk Factors ; Treatment Outcome
Keywords
Angioplasty ; Clotinab ; Myocardial infarction ; Percutaneous coronary intervention
Abstract
BACKGROUND: This study investigated the efficacy and the safety of the upstream glycoprotein (Gp) IIb/IIIa inhibitor (clotinab; ISU ABXIS, Seoul, Republic of Korea) under 600-mg clopidogrel pretreatment compared with provisional use in ST-elevation myocardial infarction (STEMI). METHODS AND RESULTS: A total of 786 STEMI patients were randomized to upstream use in the emergency room (ER) (n = 392) or provisional use during percutaneous coronary intervention (PCI) (n = 394). All patients were prescribed 600-mg clopidogrel in the ER. The primary endpoint was the 30-day incidence of composite events including death, nonfatal myocardial infarction, target vessel revascularization, and stroke. There was no significant difference in the events that occurred in 40 patients (10.2%) in the upstream arm and 55 patients (14.0%) in the provisional arm during the 30 days (odds ratio 0.70, 95% confidence interval 0.45-1.08). Major bleeding was higher in the upstream arm (1.5% vs. 0%, P = 0.02). However, there was a significant reduction in 30-day composite events in the upstream arm in the high-risk population (Killip class ≥II or GRACE score >140). CONCLUSIONS: The upstream use of clotinab under a 600-mg clopidogrel loading may not significantly reduce cardiac events following primary PCI but may improve the clinical outcome in high-risk patients.
Files in This Item:
T201200499.pdf Download
DOI
22146757
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ko, Young Guk(고영국) ORCID logo https://orcid.org/0000-0001-7748-5788
Kim, Byeong Keuk(김병극) ORCID logo https://orcid.org/0000-0003-2493-066X
Kim, Jung Sun(김중선) ORCID logo https://orcid.org/0000-0003-2263-3274
Park, Sang Min(박상민)
Jang, Yang Soo(장양수) ORCID logo https://orcid.org/0000-0002-2169-3112
Choi, Dong Hoon(최동훈) ORCID logo https://orcid.org/0000-0002-2009-9760
Hong, Myeong Ki(홍명기) ORCID logo https://orcid.org/0000-0002-2090-2031
Hong, Bum Kee(홍범기) ORCID logo https://orcid.org/0000-0002-6456-0184
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/89956
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links